Physician profile
Thomas Lubin
NPI 1174533988
$1,468.34
in general payments reported to CMS, 2019-2025
14 companies · $738 in 2025
The $738 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.57 · 2020: $18.20 · 2022: $166 · 2023: $179 · 2024: $271 · 2025: $738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,187.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $318.34 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Exact Sciences Corporation | $303.09 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $212.54 | 2024-2025 | Airsupra, Breztri |
| Novo Nordisk INC | $161.21 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $80.69 | 2024-2025 | Veozah |
| Amgen INC. | $80.15 | 2024-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $79.00 | 2024-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $71.92 | 2019-2025 | |
| Shield Therapeutics INC | $69.03 | 2025 | |
| Almatica Pharma LLC | $22.39 | 2022 | |
| Eisai INC. | $20.90 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $18.91 | 2025 | Zoryve |
| Allergan, INC. | $18.20 | 2020 | |
| Merck Sharp & Dohme LLC | $11.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Lubin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.